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. 60  ABSTRACT   
. 61  Objective: evidence is limited regarding outcome of patients with ectopic Cushing’s 
syndrome (ECS) due to   
. 62  neuroendocrine tumors (NETs).   
. 63  Design: we assessed prognostic factors affecting survival of patients with NETs and 
ECS.   
. 64  Methods: retrospective analysis of clinicopathological features, severity of hormonal 
syndrome, treatments   
. 65  from a large cohort of patients with NETs and ECS collected from 17 Italian centres.   
. 66  Results: our series included 110 patients, 58.2% female, with mean (±SD) age at 
diagnosis of 49.5 ±15.9   
. 67  years. The main sources of ectopic ACTH were: bronchial carcinoids (BC) (40.9%), 
occult tumors (22.7%)   
. 68  and pancreatic (p)NETs (15.5%). Curative surgery was performed in 56.7% (70.2% 
of BC, 11% of pNETs).   
. 69  Overall survival was significantly higher in BC compared with pNETs and occult 
tumors (p=0.033) and in   
. 70  G1-NETs compared with G2 and G3 (p=0.007). Negative predictive factors for 
survival were severity of   
. 71  hypercortisolism (p<0.02), hypokalemia (p=0.001), diabetes mellitus (p=0.0146) and 
distant metastases   
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. 72  (p<0.001). Improved survival was observed in patients who underwent NET removal 
(p<0.001).   
. 73  Adrenalectomy improved short-term survival.   
. 74  Conclusions: multiple factors affect prognosis of ECS patients: type of NET, grading, 
distant metastases,   
. 75  severity of hypercortisolism, hypokalemia and diabetes mellitus. BC have the highest 
curative surgical rate   
. 76  and better survival compared with occult tumors and pNETs. Hypercortisolism plays 
a primary role in   
. 77  affecting outcome and quality of life; therefore, prompt and vigorous treatment of 
hormonal excess by NET   
. 78  surgery and medical therapy should be a key therapeutic goal. In refractory cases, 
adrenalectomy should be   
. 79  considered, since it affects outcome positively at least in the first 2 years.   
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Introduction  
Ectopic Cushing’s syndrome (ECS) is a rare condition accounting for 10-20% of all cases of 
ACTH- dependent Cushing (1,2). Neuroendocrine tumors (NETs), mainly bronchial 
carcinoids (BC) (3-54.8%) are the most frequent causes of ectopic ACTH secretion in more 
recent series (3-8), while small cell lung carcinoma (SCLC) represented the most common 
tumor associated with ECS in early series (3.3-50%) (9). Other less frequent causes are 
thymic carcinoids (TC) (5-42%), pancreatic (p) NETs (7.5-25%), pheochromocytomas (2.5-
25%) and medullary thyroid carcinomas (MTC) (2-8%) (3-8). Unknown primary tumors 
account for 12-36.5% of all causes of ectopic ACTH production (3).  
Available data on patients affected by ECS deriving from NETs is relatively scarce and 
outdated. The largest retrospective series is from the Mayo Clinic, including 106 patients 
followed between 1958 and 1986 (5). This study addressed the clinical characteristics, 
modalities of treatment and follow up of the patients, without reporting on histopathological 
features and prognosis of the tumors. In the second most numerous retrospective study, data 
regarding performance of diagnostic tests, therapies, pathological examinations and survival 
of 90 patients from NIH between 1983 and 2004 were analysed (6). It was found that 47% 
of the whole group, represented mainly by BC, underwent curative resection compared with 
12% of the series from Mayo Clinic; patients affected by gastrinoma, MTC and SCLC 
displayed the poorest prognosis. In another series from UK including 40 patients, those 
affected by BC had the highest surgical curative rate (83%), whereas the remainders needed 
iris-AperTO 
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adrenolytic therapy or adrenalectomy to control hypercortisolism (7). Histology and distant 
metastases were the main prognostic factors.  
The aim of our study was to assess which factors affect survival on a large multicentre 
series of patients with NETs and ECS with complete clinical annotations.  Patients and 
methods  We did a retrospective analysis of data from patients with ECS from NETs 
collected in 17 Italian referral centres between 1986 and 2014, obtained by means of a 
specific questionnaire divided in different items. The study received the approval of the 
institutional ethical committees of each centre.  
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. 106  Patients with diagnosis of ECS due to NETs were identified from the institutional 
database of patients of   
. 107  each centre. Data were retrieved by medical personnel from medical records both in 
paper and electronic   
. 108  .   
. 109  The diagnosis of ECS was based on a review of the patient’s medical history, 
clinical features associated   
. 110  with cortisol excess and laboratory tests. These included increase in 24-h urinary 
free cortisol (UFC) levels   
. 111  in at least 2 samples, unsuppressed serum cortisol after 1-mg overnight 
dexamethasone suppression test   
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. 112  (DST), loss of physiological cortisol diurnal rhythm with assessment of midnight 
plasma and/or salivary   
. 113  cortisol levels and increase in ACTH levels. To differentiate between pituitary and 
ectopic ACTH production   
. 114  at least 2 of the following tests were performed: overnight 2-mg, 8-mg DST, 100-
mcg CRH test and   
. 115  desmopressin test.   
. 116  The first item of the questionnaire referred to the site of ACTH production, 
histological features of NET   
. 117  according to the 2010 WHO classification for gastroenteropancreatic (GEP) NETs 
(10) and to the 2004   
. 118  WHO classification for lung carcinoids when applicable (11), proliferative activity 
by staining for the Ki-67   
. 119  antigen or by mitotic count per 10 high–power fields, presence of local and distant 
metastases and   
. 120  association with inherited syndrome, such as multiple endocrine neoplasia (MEN) 
type 1, MEN 2 and von   
. 121  Hippel Lindau disease (VHL). Results from biopsy of the primary tumor or 
metastases were also reported   
. 122  when available.   
. 123  Diagnosis of occult/unknown primary tumor was reserved for patients with clinical 
features of   
. 124  hypercortisolism and hormonal tests suggestive of an ectopic ACTH source 
including lack of central-   
. 125  peripheral ACTH gradient during inferior petrosal sinus sampling (IPSS), without 
primary tumor localization   
. 126  after prolonged and repeated imaging follow-up established by negative radiological 
and/or nuclear medicine   
. 127  procedures, and exclusion of other tumors known to cause ECS. In 2 cases of occult 
ECS of our series   
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128  
. 129  Other items regarded clinical data, including type and duration of symptoms before 
ECS diagnosis, the   
. 130  biochemical and hormonal profile including serum potassium, 24-h UFC, serum 
cortisol at 8 a.m., at   
. 131  midnight and salivary if available, plasma ACTH, dynamic tests [overnight 1-mg, 2-
mg, 8-mg DST, 100   
. 132  mcg CRH test, desmopressin test and central-peripheral gradients of baseline and 
CRH stimulated ACTH 5   
form.  The centres were asked to report on all their series of patients with ECS due to NETs  
pituitary esploration had been performed without the finding of any pituitary lesion  (12).  
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assessed during IPSS. Considering different assay techniques, hormonal levels were 
classified in 3 categories; 1) up to 3-fold increase over the upper limit of normal (ULN) of 
the reference range of each centre, 2) between 3- to 5-fold increase, and 3) above 5-fold 
increase. Chromogranin A and neuron specific enolase (NSE) levels were also collected 
when available. Other specific items were pituitary magnetic resonance imaging (MRI) and 
diagnostic imaging procedures performed to identify the NET, including radiological an 
nuclear medicine ones. Data regarding modalities of treatments for ECS (steroidogenesis 
inhibitors, adrenalectomy) and for tumor control [surgery of the NET, antiproliferative 
agents, transcatheter arterial chemoembolization (TACE), transcatheter arterial 
embolization (TAE), radiofrequency ablation (RFA), selective internal radiation therapy 
(SIRT), peptide receptor radionuclide therapy (PRRT)] and results of treatment in terms of 
ECS control (complete or partial defined as UFC level above the ULN, but reduced by ≥ 
50% from baseline) and survival were collected.  
Statistical analysis  
The results are expressed as means (±SD) or median. Two-sample Student’s t-test was used 
to verify statistical differences between means while chi square test to evaluate the 
association between categorical variables. Values of p<0.05 were considered statistically 
significant. Survival probabilities were estimated employing the Kaplan-Meier method. 
Survival curves were compared employing the log-rank test. The joint prognostic role of 
considered variables was evaluated employing the Cox model. All the analyses were 
performed employing the software R (R Core Team (2014). R: A language and environment 
for statistical computing. R Foundation for Statistical Computing (Vienna, Austria).  
Results  
iris-AperTO 
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Clinicopathological characteristics of the patients  
The study included 110 patients (58.2% female) diagnosed with ECS from NET, with mean 
(±SD) age at  
diagnosis of 49.5 ±15.9 years. The clinicopathological characteristics of the patients are 
summarized in Table 1. The sources of ectopic ACTH were 45 (40.9%) BC (30 typical, 12 
atypical and 3 not otherwise specified), 25 (22.7%) occult/unknown primary tumors, 17 
(15.5%) pNETs, 7 (6.4%) pheochromocytomas, 6 (5.5%) TC, 4 (3.6%) SCLC, 3 (2.7%) 
intestinal (1 ileal, 1 caecal, 1 rectal) NETs, 2 (1.8%) MTC and 1 (0.9%) small cell 
carcinoma of the cervix (SCCC).  
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. 160  Ki 67% or mitotic count was available in 54 NETs, allowing stratification in 3 
groups: 1) G1 NETs   
. 161  characterized by Ki 67%/mitotic count of 0-2, including 17 typical BC, 3 pNETs, 1 
pheochromocytoma   
. 162  (38.9% of patients); 2) G2 NETs characterized by Ki 67%/mitotic count of 3-20, 
including 9 atypical BC, 6   
. 163  pNET, 3 TC, 1 pheochromocytoma, 1 caecal, 1 metastatic occult tumor; (38.9% of 
patients); 3) G3 NETs   
. 164  characterized by Ki 67%/mitotic count of >20 including 4 pNETs, 2 atypical BC, 2 
metastatic occult tumors,   
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. 165  1 SCLC, 1 TC, 1 rectal NET, 1 SCCC (22.2% of patients). Immunostaining for 
ACTH was reported positive   
. 166  in 42/52 (84.6%)   
. 167  Distant metastases were significantly (chi square=40.9; p<0.001) more prevalent in 
p-NETs (13/17, 76.5%),   
. 168  SCLC (3/4, 75%), TC (5/6 83%) and atypical BC (6/12 50%) than in typical BC 
(4/30 13.3%) and   
. 169  metastases form occult tumors (4/25 16%). No pheocromocytoma was malignant. 
One out of 2 MTC had   
. 170  distant metastases. Lymph node metastases were present in 11/30 (36.7%) typical 
BC, 8/12 (66.7%) atypical   
. 171  BC, 8/17 (47%) pNETs, 3/6 (50%) TC, 2/25 (8%) occult tumors, 2/4 (50%) SCLC, 
2/2 MTC (100%). These   
. 172  percentages were significantly different (chi square=22.7; p=0.004).   
. 173  Clinical features at diagnosis are summarized in Table 2. No significant difference 
neither in the prevalence   
. 174  of symptoms nor in the number of symptoms was found among the type of NET 
subgroups   
. 175  The mean duration of symptoms before NET diagnosis was 13.1 ± 21.2 months.   
. 176  Two (1.8%) patients (1 with pNET and 1 with typical BC) were affected by MEN1 
and 1 (0.9%) with pNET   
. 177  by Von Hippel Lindau disease.   
. 178  Laboratory data   
. 179  Hypokalemia (serum potassium <3.5 mEq/l) was present in 72 (71.3%) patients. 24-
hr UFC was increased in   
. 180  91/93 (97.8%) patients, s-cortisol at 8 a.m. in 87/105 (82.9%) and ACTH in 97/102 
(95.1%). In the 2 patients   
. 181  with normal 24-hr UFC the diagnosis of ECS was made on the basis of at least other 
2 altered tests. Serum   
iris-AperTO 
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. 182  cortisol at midnight was collected in 52/110 (47.3%) patients and was increased in 
all. No significant   
. 183  difference was observed in hormonal levels among the subgroups of NETs. A 
significant correlation was   
. 184  found between hormonal levels (s-cortisol, 24-hr UFC, ACTH) and hypokaliemia 
(p<0.05), but not between   
. 185  hormonal levels and clinical features. The laboratory data and the sensitivity of 
dynamic tests are   
. 186  summarized in Table 3.  7   
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Diagnostic procedures  In all cases (45) in which pituitary MRI was carried out no pituitary 
mass was found.  With regard to occult tumors, 21/25 patients had undergone computed 
tomography (CT), 8/25 patients MRI, 17/25, somatostatin-receptor scintigraphy (SRS), 6/25 
18F-FDG-PET/CT, 4/25 68Ga-DOTA-peptide PET/CT, 17/25 radiological imaging 
(CT/MRI) plus a functional imaging (SRS/PET), 1 colonoscopy. In 4 cases (3 typical BC 
and 1 TC), the NET was found after a mean time of 4 years (range 3-5 years) from the ECS 
diagnosis by CT scan in all, 68Ga-DOTA-peptide PET/CT in 2 and SRS in 1. Two of them 
had been submitted to adrenalectomy as first therapeutic choice.  The prevalence of occult 
tumors among patients recruited in the period between 2006 and 2014 decreased (17.2%), 
compared with those recruited in the previous periods (25% between 1986 and 1994, and 
32.4% between 1995 and 2005).  Medical treatment of ECS  The majority of patients (78/110, 
70.9%) were treated with steroidogenesis inhibitors, even in combination [ketoconazole in 
69/78 (88.5%), mitotane in 13/78 (16.7%) and metyrapone in 5/78 (6.4%)]. Other drugs 
were the glucocorticoid receptor antagonist mifepristone in 1 (0.9%), cabergoline in 8 
(7.3%) and somatostatin analogues (SA: lanreotide or octreotide LAR) in 60 (54.5%). In 
59/110 (53.6%) patients each drug was given alone, whereas in 51/110 (46.4%) in 
combination, the most used being ketoconazole plus SA (41 patients) or mitotane plus SA 
(11 patients). Steroidogenesis inhibitors were used before surgery in 33/60 patients (55%), 
and after surgery in 4/60 (6.6 %). Complete hormonal control was achieved in 15/51 
(29.4%) and partial control in 36/51 (70.6%) patients who received only medical treatment.  
Surgical treatment of the NET and adrenalectomy  
Sixty out of 110 (54.5%) patients underwent etiologic surgery: 37/45 (82.2%) BC (8 
atypical, 26 typical, 3 unspecified), 9/17 (52.9%) pNET, 5/6 (83.3%) TC, 5/7 (71.4%) 
pheocromocytomas, 1 SCCC, 1 ileal NET, 1 MTC and 1 patient who resulted a false 
positive. Curative surgery was obtained in 34/60 (56.7%): 26/37 (70.2%) BC (21 typical, 4 
atypical, 1 not otherwise specified), 1/9 (11.1%) pNETs , 5/5 pheocromocytomas (100%), 1 
TC, 1 ileal NET. In 8 ECS relapsed (4 typical BC, 1 atypical BC, 2 BC not otherwise 
specified, 1 pNET), after a mean time of 5.2 years from surgery. Palliative surgery, i.e. 
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. 214  presence of distant metastases was performed in 16/60 patients (26.6%), of whom 1 
typical BC, 3 atypical   
. 215  BC, 4 TC, 7 pNETs, and 1 SCCC.   
. 216  Thirty-one (28.2%) patients underwent adrenalectomy: 18 as primary treatment (5 
BC, 1 TC, 4 pNETs, 8   
. 217  occult tumors), and 13 following other treatments (4 BC, 3 pNETs, 2 TC, 4 occult 
tumors). Five out of 31   
. 218  patients (2 pNETs, 1 BC, 1 TC, 1 occult tumor) underwent monolateral 
adrenalectomy due to poor clinical   
. 219  conditions with the intent of 2-step adrenalectomy. The prevalence of patients who 
underwent adrenalectomy   
. 220  was significantly higher in occult tumors and p-NETs compared with BC (48% and 
41.2% vs 20%, p=   
. 221  0.038).   
. 222  Antineoplastic treatment   
. 223  As additional therapy, 8 (7.3%) patients (1 BC, 1 TC, 5 pNETs, 1 occult tumor) 
iris-AperTO 
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received Everolimus and 1   
. 224  (0.9%) patient (pNET) Sunitinib. Chemotherapy was performed in 27 (24.5%) 
patients including   
. 225  strepto/doxo/5FU in 3 patients (1 atypical BC, 1 TC, 1 pNET), etoposide/cisplatin in 
14 patients (2 atypical   
. 226  BC, 2 SCLC, 3 TC, 4 pNETs, 1 SCCC, 2 occult tumors) and 
temozolomide/capecitabine 10 patients (1   
. 227  typical BC, 1 atypical BC, 1 TC, 5 pNETs, 1 occult tumor, 1 caecal NET). 
Chemotherapy was administered   
. 228  alone in 12 (44.4%) patients, in combination with surgery of the NET in 12 patients 
and after tumor relapse   
. 229  in 3 (11.1%) patients.   
. 230  TACE/TAE of liver metastases were performed in 5 (4.5%, all pNETs) patients, 
RFA in 3 (2.7%) of whom 2   
. 231  pNET, 1 BC, SIRT in 1 (0.9%) BC. PRRT was carried out in 13 (11.8%) (6 BC, 2 
TC, 5 pNETs) of whom   
. 232  10 (76.9%) obtained a partial or complete ECS control.   
. 233  Follow up and survival rate   
. 234  Considering the whole population of 110 patients the median follow up (from 
diagnosis to last evaluation)   
. 235  was 60 months. During the follow-up period, 30 patients died: 18 patients (2 typical 
BC, 2 atypical BC, 2   
. 236  TC, 5 pNETs, 1 caecal, 1 SCCC, 1 MTC, 4 occult tumors) due to tumor progression, 
11 patients (2 typical   
. 237  BC, 2 SCLC, 2 pNETs, 1 rectal, 4 occult tumors) due to the consequences of cortisol 
excess (4 respiratory   
. 238  failure secondary to thromboembolism or pneumonia, 1 acute myocardial infarction, 
5 septic shock, 1 severe   
. 239  hypokalemia) and 1 patient with occult tumor died for breast adenocarcinoma.  9   
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The overall survival (OS) was: 84% at 1 year of follow up, 81% at 2 years, 74% at 3 years, 
70% at 4 and 5 years.  Patients ≥60-yr-old at diagnosis had a worse prognosis than younger 
patients (5-yr OS 52% vs 81% <40 yr- old and vs 77% between 40-59 yrs old at diagnosis, 
p=0.016).  
There was no statistically significant difference in OS according to gender and period of 
diagnosis.  The 5-yr OS rate for BC was significantly higher than that for pNETs and occult 
tumors (86% vs 60% for latter groups, p=0.033) (Figure 1). With regard to the histologic 
grade, there was a significant trend toward worsening of 5-yr OS for G1, G2 and G3-NETs 
(87.7%, 72.4%, 37.0% respectively; p=0.007).  Patients with metastases had a poorer 
prognosis than those without (5-yr OS: 79% vs 61%, p=0.019). This was true in particular 
for patients with distant metastases (5-yr OS: 82% vs 47%, p<0.001) (Figure 2). 
Considering the s-cortisol levels a worse survival rate was found in the group with >3-fold 
increase compared with the groups with up to 3-fold increase (p<0.001). Similarly for 24-hr 
UFC and ACTH, patients with > 5-fold increase had a worse survival rate compared with 
patients with up to 5-fold increase (p=0.005 and p=0.01, respectively) (Figure 3). The 
presence of hypokalemia (<3.5 mEq/L) (p=0.001) and diabetes mellitus (p=0.0146) were 
negative prognostic factors.  Patients who underwent etiologic surgery had a better survival 
rate than those who did not (5-yr OS 85% vs 51%, p<0.001) (Figure 4). Patients who 
underwent adrenalectomy had a better survival rate in the first 2 years compared with those 
who did not. During the first 2 years of follow-up there were no deaths in the former group 
vs 18 deaths in the latter, with a 2-year overall survival of 74%, although the 5-yr OS was 
not significantly different (76% vs 68%, p=0.168).  The Cox model was employed to 
evaluate the joint effect of the following variables: age at diagnosis, distant metastases, NET 
surgery, adrenalectomy, Ki-67 and 24-hr UFC. A significance prognostic role (p<0.001) 
was found for distant metastases and NET surgery. For the first variable the hazard ratio 
(yes vs no) was 5.4 (95% C.I.: 2.2-13.3), while for the second (no vs yes) was 6.1 (95% 
C.I.: 2.4-15.7). Also the ≥5-fold increase over ULN of 24-hr UFC was significantly 
associated with worse prognosis (p=0.012); the estimate of the hazard ratio was 6.5 (95% 
C.I.: 1.5-28.2).  
10  
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. 267  Discussion   
. 268  The aim of our study was to assess the factors affecting survival in patients with 
ECS due to NETs. The   
. 269  strengths of our study are the sample size, the largest up to now reported, and the 
complete clinical   
. 270  annotation of our patients allowing assessment of factors never previously examined 
on a large scale. We   
. 271  acknowledge the limitation of the retrospective and multicentre nature of the study.   
. 272  The major finding of our study is that the severity of cortisol excess impacts on 
survival. Hypercortisolism   
. 273  causes severe comorbidities due to its effects on glucose and lipid metabolism, the 
cardiovascular system,   
. 274  skeletal turnover and the immune system (13-16). It is known that the consequences 
of hypercortisolism can   
. 275  lead to the death of the patient, sometimes more rapidly than tumor progression (17, 
18). However, until now   
. 276  the correlation between cortisol excess and survival had not yet been demonstrated 
on a large scale. We have   
. 277  herein shown that the severity of cortisol excess significantly affects overall survival 
and that the increase in   
. 278  24-hr UFC is an independent negative prognostic factor. This is a key clinical 
message for an appropriate   
. 279  management of ECS, prompting that a vigorous control of the hormonal syndrome 
should be one of the main   
. 280  therapeutic goals. Our results show that the outcome of patients with ECS did not 
improve over the 30 years   
. 281  of the study. As hypercortisolism is among the major causes of a poor prognosis in 
iris-AperTO 
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these patients, it seems   
. 282  advisable to actively counteract it with a more rapid and effective medical therapy 
or, in case of failure, an   
. 283  early bilateral adrenalectomy.   
. 284  Our study also demonstrates how tumor grading and staging affect the prognosis of 
these patients. This is the   
. 285  first study to demonstrate that survival is progressively and significantly improved 
for moderate and well   
. 286  differentiated NETs compared with that for poorly differentiated NETs. Overall 
survival was significantly   
. 287  worse for patients with distant metastases, as already shown in other studies (7,8).   
. 288  Considering the site of the primary tumor, BC were confirmed to be the most 
prevalent source of ectopic   
. 289  ACTH, as reported in the most recent series (5-8). Typical BC were more frequent 
than atypical BC (66% vs   
. 290  26.6%) and showed a more favourable behaviour with less lymph node and distant 
spread (36.7% vs 66.7%   
. 291  and 13% vs 50% respectively). Surgery was curative in a high proportion of patients 
with BC (70.2%) even   
. 292  in the presence of positive lymph nodes without the need of post-operative 
mediastinal radiotherapy.  11   
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Moreover, BC showed a significantly better survival rate compared with that of pNETs and 
occult tumors. The favourable survival rate of BC compared with other ACTH-secreting 
tumors had already been observed in other studies (6, 7, 19). Conversely, survival rate of 
occult tumors in our series was poorer than that of BC and similar to that of pNET, in 
contrast to the results reported by Ilias et al. (6). Pancreatic NETs were the most frequent 
source of ECS among GEP-NETs; they were usually of great size with distant metastases. 
The majority of pNETs (9/13) were well differentiated (G2 and G1) as found in a recent 
report (20). These tumors did not have distinctive histological features compared with 
pNETs without ECS; however, they displayed signs of aggressiveness including vascular 
and perineural invasion. In our study the outcome of pNETs was worse compared with that 
of BC, with a lower curative surgical rate (11% vs 70.2%) and a lower 5-yr OS (60% vs 
iris-AperTO 
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86%).  
A significant percentage of tumors in our series (22.7%) remained occult after diagnostic 
work-up.  
There is a current debate on the possibility of the presence of Cushing’s disease in the 
patient with negative IPSS without evidence of ectopic tumor (21). In only 2 cases of our 
series pituitary exploration had been performed without the finding of any pituitary lesion. 
The majority of our centres did not routinely perform surgical exploration of the pituitary in 
presence of concordant dynamic tests for ECS and negative IPSS. Only 4/25 patients had 
undergone 68Ga-DOTA-peptide PET/CT, which is known to be highly sensitive in detecting 
NETs due to the limited and only recent availability among the centres. Some BC may be 
too small to be identified by CT scan or show heterogeneity of SSTR expression preventing 
them from being visualized by SRS (22). It is worth noting that in some cases the negative 
somatostatin receptor scintigraphy or 68Ga-DOTA-peptide PET/CT can be due to down-
regulated SSTR expression after long-term exposure to hypercortisolism (23,24).  
The survival rate of patients with occult tumors and ECS was similar to that of patients with 
pNETs but worse than that of patients with BC due to the metastatic spread or the 
consequences of hypercortisolism. Only one third of the patients (8/25) with occult tumors 
underwent adrenalectomy as first treatment. In our series, patients with a higher increase in 
hormonal levels or a presence of hypokalemia and diabetes mellitus, and those who did not 
perform surgery of the NET had a worse prognosis. Furthermore, patients who underwent 
adrenalectomy had a better survival rate at least in the first 2 years, highlighting the 
importance of  
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. 320  prompt control of hypercortisolism. Nowadays, laparoscopic adrenalectomy is a safe 
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional Repository 
and minimally invasive   
. 321  surgical treatment (25); thus, it should be considered more frequently as an option in 
the management of   
. 322  ECS, in particular in early stages, when the hormonal syndrome is not controlled by 
medical treatment   
. 323  and/or persists after surgical removal of the primary tumor.   
. 324  Concerning the outcome of medical therapy, the variability of treatments employed 
did not allow us to draw   
. 325  a definitive conclusion.   
. 326  In our experience, PRRT was an effective therapeutic option when SRS or 68Ga-
DOTA-peptide-PET/CT are   
. 327  positive, attaining partial or complete hormonal control in 76.9% of patients.   
. 328  Conclusions   
. 329  Several factors have an impact on prognosis of patients with ECS, namely, NET 
type, grading, presence of   
. 330  distant metastases, severity of hypercortisolism, hypokalemia and diabetes mellitus. 
BC have the highest   
. 331  curative surgical rate and better survival than occult tumors, which still account for 
23% of cases, and   
. 332  pNETs. Cortisol excess plays a major role in affecting duration and quality of life; 
therefore, a prompt   
. 333  treatment directed toward the primary tumor and inhibiting adrenal function is a key 
therapeutic goal. In   
. 334  refractory cases, adrenalectomy should be considered, since it affected positively 
patients’ outcome at least   
. 335  in the first 2 years.   
336  
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. 413  Figure legends:   
. 414  Figure 1. Overall survival by neuroendocrine tumor (NET). BC: bronchial carcinoid; 
pNET, pancreatic   
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. 415  NET, occult tumor. Number of patients at risk at 12, 24, 36, 48, 60 months are 36, 
32, 27, 24, 21 (BC), 11,   
. 416  10, 8, 6, 4 (pNET), 18, 16, 13, 10, 10 (Occult tumor). Survival probabilities were 
estimated employing the   
. 417  Kaplan-Meier method. Survival curves were compared employing the log-rank test.   
. 418  Figure 2. Overall survival by distant metastases. Number of patients at risk at 12, 24, 
36, 48, 60 months are   
. 419  21, 17, 10, 9, 7 (Yes), 57, 52, 45, 37, 31(No). Survival probabilities were estimated 
employing the Kaplan-   
. 420  Meier method. Survival curves were compared employing the log-rank test.   
. 421  Figure 3. Overall survival by 24-hr UFC levels. UFC: urinary free cortisol; ULN: 
upper limit of normal.   
. 422  Number of patients at risk at 12, 24, 36, 48, 60 months are 23, 20, 16, 14, 11 (up to 5 
ULN), 40, 36, 32, 26,   
. 423  21 (> 5 ULN). Survival probabilities were estimated employing the Kaplan-Meier 
method. Survival curves   
. 424  were compared employing the log-rank test.   
. 425  Figure 4. Overall survival by neuroendocrine tumor (NET) surgery. Number of 
patients at risk at 12, 24, 36,   
. 426  48, 60 months are 49, 46, 37, 33, 26 (Yes), 29, 23, 18, 13,12 (No). Survival 
probabilities were estimated   
. 427  employing the Kaplan-Meier method. Survival curves were compared employing 
the log-rank test.   
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Table 1. Clinicopathological characteristics of the patients  
          
   
BC  Occult tumors pNETs Pheochromocytomas TC  SCLC  Intestinal NETs MTC  SCCC  
Source of ectopic ACTH - no. (%)  
45 (40.9) 25 (22.7) 17 (15.5) 7 (6.4)  
6 (5.5) 4 (3.6) 3 (2.7) 2 (1.8) 1 (0.9)  
Mean ± SD age at diagnosis (yrs)  
44.9 ± 16.6 55.4 ± 13.5* 48.3 ± 14.7 50.1 ±17 42±14  
69.7 ± 7.6* 66±9 57.5 ± 3.5 24  
Mean ± SD tumor diameter  
(mm) 23.4 ± 18  
-  48.4 ± 34.7* 26.5 ± 14 57.4 ± 9.9* 33.3 ± 5.8 21.5 ± 13.4 30  42  
Mean ± SD symptom duration before diagnosis (months)  
16.5 ± 24.5 18.5 ±28.3 3.9 ± 5.6* 11 ± 8.5 11.6 ± 8.3 3.25 ± 2.1* 13 ± 19.92 6.5  
5  
Distant metastases - no./total no. (%)  
9/36 (20) 4/25 (16) 13/17 (76)* 0/7 (0) 5/6(83)* 3/4 (75)* 2/3 (66.7) 1/2 (50) 1/1 (100)  
Lymph node metastases - no./total no. (%)  
20/45 (44.4)* 2/25 (8) 8/17(52.9)* 0/7 (0)  
3/6 (50)* 2/4 (50)* 1/3 (33.3) 2/2 (100) 1/1 (100)  
       
*p < 0.05; NETs, neuroendocrine tumors; BC, bronchial carcinoid; pNETs, pancreatic neuroendocrine tumors; 
TC, thymic carcinoids; SCLC, small cells lung cancer; MTC, medullary thyroid carcinoma; SCCC, small cells 
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cervical carcinoma; SD, standard deviation.  
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Table 2. Clinical features at diagnosis Clinical features at diagnosis %  
Hypertension 89.1 Diabetes mellitus 65.5 Proximal myopathy 70.9 Skin fragility 
54.5 Osteoporosis 48.2 Psychiatric diseases 34.5 Hypercoagulability 30 Serum 
potassium <3.5 mEq/L 71.3  
  
 
eje@bioscientfica.com  
For Review 
Only  
Page 21 of 24  
Manuscript submitted for review to European Journal of Endocrinology  
Table 3. Laboratory data and sensitivity of dynamic tests  
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Laboratory data  
Normal  <3 times ULN 3-5 times ULN >5 times ULN  
Dynamic Tests  
24hUFC -no./total no. (%)  
2/93 (2.2) 19/93 (20.4) 7/93 (7.5) 65/93 (69.9)  
8 a.m. ACTH  – no./total no. (%)  
5/102 (4.9) 48/102 (47.6) 24/102 (23.5) 25/102 (24.5)  
no./total no.(%)  
63/63 (100) 13/13 (100) 60/70 (85.7) 55/58 (94.8) 20/26 (76.9) 25/28 (89.3)  
8 a.m. S-cortisol  - no./total no. (%)  
    
18/105 (17.1) 68/105 (64.8) 10/105 (9.5)  
9/105 (8.6)  
      
Overnight 1-mg DST (not suppressed) 2-mg DST (not suppressed)  HDDST (not suppressed)  CRH test (no 
response)  
Desmopressin test (no response)  IPSS (no gradient at baseline and after CRH)  
  
ACTH, adrenocorticotropic hormone; ULN, upper limit of normal; UFC, urinary free cortisol; DST, 
dexamethasone; HDDST, high dose dexamethasone suppression test; CRH, corticotropin releasing hormone; 
IPPS, inferior petrosal sinus sampling.  
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Figure 1. Overall survival by neuroendocrine tumor (NET). BC: bronchial 
carcinoid; pNET, pancreatic NET, occult tumor. Number of patients at risk at 
12, 24, 36, 48, 60 months are 36, 32, 27, 24, 21 (BC), 11, 10, 8, 6, 4 (pNET), 
18, 16, 13, 10, 10 (Occult tumor). Survival probabilities were estimated 
employing the  
Kaplan-Meier method. Survival curves were compared employing the log-rank 
test. Figure 1  
175x175mm (300 x 300 DPI)  
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Figure 2. Overall survival by distant metastases. Number of patients at risk at 
12, 24, 36, 48, 60 months are 21, 17, 10, 9, 7 (Yes), 57, 52, 45, 37, 31(No). 
Survival probabilities were estimated employing the Kaplan- Meier method. 
Survival curves were compared employing the log-rank test. Figure 
2 175x175mm (300 x 300 DPI)  
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Figure 3. Overall survival by 24-hr UFC levels. UFC: urinary free cortisol; ULN: 
upper limit of normal. Number of patients at risk at 12, 24, 36, 48, 60 months 
are 23, 20, 16, 14, 11 (up to 5 ULN), 40, 36, 32, 26, 21 (> 5 ULN). Survival 
probabilities were estimated employing the Kaplan-Meier method. Survival 
curves were compared employing the log-rank test. Figure 3 175x175mm (300 
x 300 DPI)  
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Figure 4. Overall survival by neuroendocrine tumor (NET) surgery. Number of 
patients at risk at 12, 24, 36, 48, 60 months are 49, 46, 37, 33, 26 (Yes), 29, 
23, 18, 13,12 (No). Survival probabilities were estimated employing the 
Kaplan-Meier method. Survival curves were compared employing the log-rank 
test. Figure 4 172x172mm (300 x 300 DPI)  
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